AtriCure to Announce First Quarter 2013 Financial Results Business Wire WEST CHESTER, Ohio -- April 8, 2013 AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, will release its financial results for the first quarter of 2013 on Thursday, May 2, 2013. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 2, 2013 to discuss its first quarter 2013 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com. Pre-registration is available and recommended for this call at the following URL: https://www.theconferencingservice.com/prereg/key.process?key=PHAHEE3NP You may also access this call through an operator by calling (888) 680-0892 for domestic callers and (617) 213-4858 for international callers at least 15 minutes prior to the call start time using reservation code 31020101. The webcast will be available on AtriCure’s website and a telephonic replay of the call will also be available through June 2, 2013. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. The reservation code is 45139601. About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative Atrial Fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of Atrial Fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide.The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide. Contact: AtriCure, Inc. Vice President and Chief Financial Officer Andy Wade, 513-755-4564 firstname.lastname@example.org or Investor Relations: Westwicke Partners Lynn Pieper, 415-202-5678 Lynn.email@example.com
AtriCure to Announce First Quarter 2013 Financial Results
Press spacebar to pause and continue. Press esc to stop.